We’re proud to be a returning exhibitor at the 2026 BioSpark Annual Conference. The meeting gathers over 250 industry leaders, researchers, investors, and entrepreneurs from the global biotechnology sector for exciting talks, interactive panel discussions, and networking opportunities. Come swing by our booth to learn more about our humanized mouse models and antibody discovery services.
What is Biospark?
Biospark is a non-profit organization, based in MA, that inspires life science professionals to collaborate, connect, and build networks. The association aims to acknowledge career successes and accomplishments, as well as aspire to become the future leaders of biotech development. This is a fantastic opportunity to stay connected with the wider Boston biotech community and keep up to date with the latest developments across the sector.
Event Overview
Date: September 12th, 2026
Venue: MIT, 70 Memorial Drive, Cambridge, MA 02142
Event Schedule
For more information, please refer to the BioSpark website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
